Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311301 | 0.92 | MAPK14 (0.75) | MAPK14 | |
| SCHEMBL1310882 | 0.90 | MAPK14 (0.56) | MAPK14ALDH1A1MEN1HPGDKMT2A | |
| SCHEMBL1310635 | 0.84 | MAPK14 (0.64) | MAPK14ALDH1A1MEN1KMT2A | |
| SCHEMBL1311180 | 0.83 | MAPK14 (0.85) | MAPK14 | |
| SCHEMBL1310925 | 0.82 | MAPK14 (0.85) | MAPK14 | |
| SCHEMBL9101724 | 0.80 | MAPK14 (0.70) | MAPK14 | |
| SCHEMBL1311225 | 0.78 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL1310858 | 0.78 | MAPK14 (0.80) | MAPK14 | |
| SCHEMBL1312162 | 0.78 | MAPK14 (0.77) | MAPK14 | |
| SCHEMBL1311202 | 0.78 | MAPK14 (0.79) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455495-B2 | Pyridazino-pyridinone compounds and methods of use | AMGEN INC. (US) | 2013-06-04 | — | — | US | claimed |
| EP-2334674-B1 | Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases. | AMGEN INC (US) | 2012-06-06 | — | — | EP | claimed |
| US-20110275629-A1 | Pyridazino-pyridinone Compounds and Methods of Use | AMGEN INC. (US) | 2011-11-10 | — | — | US | claimed |
| EP-2334674-A1 | PYRIDAZINO- PYRIDINONE COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE MEDIATED DISEASES. | Amgen, Inc (US) | 2011-06-22 | — | — | EP | claimed |
| WO-2010025201-A1 | PYRIDAZINO- PYRIDINONE COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE MEDIATED DISEASES. | AMGEN INC. (US) | 2010-03-04 | — | — | WO | claimed |
| US-8455495-B2 | Pyridazino-pyridinone compounds and methods of use | AMGEN INC. (US) | 2013-06-04 | — | — | US | disclosed |
| EP-2334674-B1 | Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases. | AMGEN INC (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20110275629-A1 | Pyridazino-pyridinone Compounds and Methods of Use | AMGEN INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2334674-A1 | PYRIDAZINO- PYRIDINONE COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE MEDIATED DISEASES. | Amgen, Inc (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010025201-A1 | PYRIDAZINO- PYRIDINONE COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE MEDIATED DISEASES. | AMGEN INC. (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275629-A1 | Pyridazino-pyridinone Compounds and Methods of Use | MAPK1, MAP3K1, MAP4K2 | MAPK14 46/4885ALDH1A1 2382/4885MEN1 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.